Efficacy of levetiracetam as the first line anti- epileptic drug in management of neonatal seizures
Loading...
Date
2019-09
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Background: Neonatal seizure management has not changed much in the last 50 years. Neuronal apoptosis in animal models and cognitive impairment in human subjects has been reported with the use of Phenobarbitone. Levetiracetam is advantageous as it is effective, well tolerated and has least drug interactions.Methods: This double blinded, randomized, parallel group, active controlled study was conducted among 66 neonates in the Neonatal intensive care unit of a tertiary care hospital for a period of 18 months. Neonates with seizures fulfilling the inclusion criteria were treated either with Phenobarbitone or Levetiracetam. Seizure control was defined as no seizure activity within 40 minutes of the administration of the first drug. Failure of first line agent was treated with Phenytoin. Neonates were observed for a period of 14 weeks for recurrence of seizure and any serious adverse effects.Results: Effective seizure control was achieved in 64.7% neonates in Levetiracetam group as compared to 31.2% in Phenobarbitone group (p <0.05). Early resumption of breast feeds within 6 hours of therapy was achieved in 73.5% neonates treated with Levetiracetam compared to 31.2% neonates treated with Phenobarbitone (p value = 0.001).Conclusions: Levetiracetam is a promising alternative as first line Anti-epileptic drug in neonates with seizures. Prolonged sedation was the adverse effect noted to Phenobarbitone that made breast feeding and neuro- assessment difficult. No serious adverse effects were seen with Levetiracetam.
Description
Keywords
Antiepileptic drug, Levetiracetam, Phenobarbitone, Neonate, Efficacy, Newborn seizures, Randomized controlled study
Citation
Kaushik Ragunathan, Chandrasekhar Jayakumar. Efficacy of levetiracetam as the first line anti- epileptic drug in management of neonatal seizures. International Journal of Contemporary Pediatrics. 2019 Sep; 6(5): 2162-2168